{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:50:10Z","timestamp":1787161810549,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.nucmedbio.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:50:23Z","timestamp":1661302223000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of the \u03b1-synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs"],"prefix":"10.1016","volume":"114-115","author":[{"given":"Nakul Ravi","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Aabye","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Shalgunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafat","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto Maria","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Eufaula","family":"Beaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M\u00f8ller","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Manfred","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Demant","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Plav\u00e9n-Sigray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Moos","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.nucmedbio.2022.08.001_bb0005","first-page":"II3","article-title":"Pathoanatomy of Parkinson's disease","volume":"247","author":"Braak","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","article-title":"Pathological roles of \u03b1-synuclein in neurological disorders","volume":"10","author":"Vekrellis","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0020","series-title":"Handb Clin Neurol","first-page":"339","article-title":"Alpha-synucleinopathies","volume":"145","author":"Alafuzoff","year":"2017"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0025","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2017.11.002","article-title":"The neuropathology of multiple system atrophy and its therapeutic implications","volume":"211","author":"Valera","year":"2018","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","article-title":"The diagnosis of Parkinson's disease","volume":"5","author":"Tolosa","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00259-011-1976-9","article-title":"Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms","volume":"39","author":"Ziebell","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41181-019-0070-7","article-title":"Current radiotracers to image neurodegenerative diseases","volume":"4","author":"Tiepolt","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0055","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/ph14090847","article-title":"Alpha-synuclein PET tracer development\u2014an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0060","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/jnc.15516","article-title":"The role of neuroimaging in Parkinson's disease","volume":"159","author":"Bidesi","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0065","article-title":"[11C]MODAG-001\u2014towards a PET tracer targeting \u03b1-synuclein aggregates","author":"Kuebler","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/alz.043249","article-title":"Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies","volume":"16","author":"Capotosti","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0075","series-title":"NuklearMedizin","first-page":"L25","article-title":"Translational study of a novel alpha-synuclein PET tracer designed for first-in-human investigating","volume":"vol. 58","author":"Hooshyar Yousefi","year":"2019"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0080","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1021\/acschemneuro.0c00523","article-title":"Identification and evaluation of bisquinoline scaffold as a new candidate for \u03b1-synuclein-PET imaging","volume":"11","author":"Kaide","year":"2020","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0085","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.8b00229","article-title":"In silico, in vitro, and in vivo evaluation of new candidates for \u03b1-synuclein PET imaging","volume":"15","author":"Verdurand","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0090","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0100","article-title":"11C radiolabeling of anle253b: a putative PET tracer for Parkinson's disease that binds to alpha-synuclein fibrils in vitro and crosses the blood-brain barrier","author":"Maurer","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.847074","article-title":"An in vivo pig model for testing novel positron emission tomography radioligands targeting cerebral protein aggregates","volume":"16","author":"Raval","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0110","series-title":"An FMRI-compatible system for targeted electrical stimulation","author":"J\u00f8rgensen","year":"2021"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0115","series-title":"An in vivo pig model for testing novel PET radioligands targeting cerebral protein aggregates. bioRxiv","author":"Raval","year":"2022"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0120","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2967\/jnumed.107.045351","article-title":"Impact of image-space resolution modeling for studies with the high-resolution research tomograph","volume":"49","author":"Sureau","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0125","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1109\/TMI.2013.2261313","article-title":"Attenuation correction for the HRRT PET-scanner using transmission scatter correction and total variation regularization","volume":"32","author":"Keller","year":"2013","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneumeth.2017.11.008","article-title":"Automatic delineation of brain regions on MRI and PET images from the pig","volume":"294","author":"Villadsen","year":"2017","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneumeth.2010.07.041","article-title":"A three-dimensional digital segmented and deformable brain atlas of the domestic pig","volume":"192","author":"Saikali","year":"2010","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0140","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","article-title":"Distribution volume ratios without blood sampling from graphical analysis of PET data","volume":"16","author":"Logan","year":"1996","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"issue":"77","key":"10.1016\/j.nucmedbio.2022.08.001_bb9000","article-title":"Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability","volume":"10","author":"Tjerkaski","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb9005","article-title":"Kinfitr: Reproducible PET pharmacokinetic modelling in R","author":"Matheson","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0150","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical use and utility of amyloid imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.113.136069","article-title":"Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers","volume":"55","author":"Shah","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3233\/JPD-130247","article-title":"\u03b1-Synuclein imaging: a critical need for Parkinson's disease research","volume":"3","author":"Eberling","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.nucmedbio.2021.03.011","article-title":"Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals","volume":"96\u201397","author":"Klenner","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1124\/dmd.118.083311","article-title":"Porcine prediction of pharmacokinetic parameters in people: a pig in a poke?","volume":"46","author":"Tang","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","article-title":"Distinct \u03b1-synuclein strains and implications for heterogeneity among \u03b1-synucleinopathies","volume":"109","author":"Peng","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nucmedbio.2022.08.001_bb0185","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1074\/jbc.RA119.012179","article-title":"\u03b1-Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species","volume":"295","author":"Morgan","year":"2020","journal-title":"J Biol Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122020704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122020704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:57Z","timestamp":1760848257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805122020704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S0969805122020704"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.08.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.05.479231","asserted-by":"object"}]},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the \u03b1-synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}